Brandywine Global Investment Management LLC Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Brandywine Global Investment Management LLC lifted its stake in Royalty Pharma plc (NASDAQ:RPRX) by 7.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,958,302 shares of the biopharmaceutical company’s stock after purchasing an additional 142,176 shares during the quarter. Brandywine Global Investment Management LLC’s holdings in Royalty Pharma were worth $49,956,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of RPRX. Allstate Corp bought a new position in shares of Royalty Pharma during the 4th quarter valued at $299,000. DnB Asset Management AS lifted its holdings in Royalty Pharma by 4.5% in the 4th quarter. DnB Asset Management AS now owns 71,106 shares of the biopharmaceutical company’s stock worth $1,814,000 after purchasing an additional 3,033 shares in the last quarter. Norges Bank purchased a new position in shares of Royalty Pharma during the fourth quarter valued at about $124,498,000. Homestead Advisers Corp raised its stake in Royalty Pharma by 3.9% during the fourth quarter. Homestead Advisers Corp now owns 1,931,140 shares of the biopharmaceutical company’s stock valued at $49,263,000 after purchasing an additional 73,000 shares in the last quarter. Finally, Sava Infond d.o.o. purchased a new position in Royalty Pharma in the fourth quarter worth about $536,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on RPRX. Citigroup restated a “buy” rating on shares of Royalty Pharma in a research report on Friday. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $41.60.

Royalty Pharma Stock Down 0.9 %

NASDAQ RPRX opened at $31.37 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The business’s fifty day simple moving average is $32.44 and its 200-day simple moving average is $28.85. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The firm has a market cap of $18.08 billion, a PE ratio of 21.63, a P/E/G ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, equities analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were given a dividend of $0.22 per share. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.81%. The ex-dividend date was Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is presently 60.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.